Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zenas BioPharma Inc.

8.25
-0.4800-5.50%
Post-market: 8.250.00000.00%16:23 EDT
Volume:176.22K
Turnover:1.49M
Market Cap:344.84M
PE:-0.69
High:9.08
Open:8.84
Low:8.10
Close:8.73
Loading ...

Zenas Biopharma Inc : Morgan Stanley Cuts Target Price to $35.00 From $40.00

THOMSON REUTERS
·
11 Dec 2024

Strategic Shift and Positive Outlook Justify Buy Rating for Zenas BioPharma, Inc.

TIPRANKS
·
11 Dec 2024

Zenas BioPharma’s Promising Pipeline and Strategic Moves Earn Buy Rating

TIPRANKS
·
14 Nov 2024

Zenas BioPharma reports Q3 EPS ($5.02), consensus ($9.33)

TIPRANKS
·
12 Nov 2024

Press Release: Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Dow Jones
·
12 Nov 2024

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

GlobeNewswire
·
12 Nov 2024

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

GlobeNewswire
·
07 Nov 2024

Zenas BioPharma initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
05 Nov 2024

Opening Day: Another trio of biotech IPOs make Friday debut

TipRanks
·
14 Oct 2024

Guggenheim Initiates Zenas BioPharma at Buy With $45 Price Target

MT Newswires Live
·
08 Oct 2024

Morgan Stanley Initiates Zenas BioPharma at Overweight With $40 Price Target

MT Newswires Live
·
08 Oct 2024

Jefferies Initiates Zenas BioPharma at Buy With $35 Price Target

MT Newswires Live
·
08 Oct 2024

Zenas BioPharma Initiated at Buy by Guggenheim

Dow Jones
·
08 Oct 2024

Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Zenas BioPharma, Inc. (ZBIO)

TIPRANKS
·
08 Oct 2024

Buy Rating for Zenas BioPharma: Innovative B-cell Therapy Approach with Market Potential

TIPRANKS
·
08 Oct 2024

Zenas BioPharma initiated with a Buy at Jefferies

TIPRANKS
·
08 Oct 2024